Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”

Documenti analoghi

• Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
  di: Polly Paul, et al.
  Pubblicazione: (2025)
• Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
  di: Nisha Sharma, et al.
  Pubblicazione: (2024)
• Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe
  di: Lisa Hanquet, et al.
  Pubblicazione: (2026)
• Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing
  di: Ian T.T. Liu, et al.
  Pubblicazione: (2026)
• Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
  di: Karen Rowland Yeo, et al.
  Pubblicazione: (2024)